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BACKGROUND: Because of the poor outcomes for patients with recurrent glioblastoma multiforme (GBM), and some laboratory and
clinical evidence of efficacy using interferon in GBM, we assessed the toxicity and efficacy of temozolomide (TMZ) combined with
either short-acting (IFN) or long-acting (pegylated) interferon a2b (PEG) in two single-arm phase II studies, and compared the results
to 6-month progression-free survival (PFS-6) data from historical controls.
METHODS: Two single-arm phase II studies were carried out in adults with GBM. Patients were treated with the standard regimen of
TMZ (150–200mgm
 2 per day   5 days every month) combined with either 4 million units per m
2 subcutaneously (SQ) three
times weekly of IFN or 0.5mgkg
 1 SQ weekly of PEG. Physical exams and imaging evaluations were carried out every 8 weeks.
RESULTS: On the IFN study, 34 adults (74% men) were enrolled, and 29 adults (55% men) on the PEG study; median Karnofsky
performance status was 80 and 90 for the IFN and PEG studies, respectively. Grade 3 or 4 toxicities were common, leucopoenia and
thrombocytopoenia occurring in 35–38% and 18–21% of patients, respectively. Grade 3 or 4 fatigue occurred in 18% of patients on
both studies. Lymphopoenia was infrequent. PFS-6 was 31% for 29 evaluable patients in the IFN study and 38% for 26 evaluable
patients in the PEG study.
CONCLUSION: In recurrent GBM patients, both studies of standard dose TMZ with either IFN or PEG showed improved efficacy when
compared to historical controls, or reports using TMZ alone. Even though the TMZþPEG study met criteria for further study, the
results of both of these studies must be considered in light of the standard of care (TMZ plus radiotherapy) for newly diagnosed
GBM, which has evolved since the inception of these studies. Despite the results of the current studies being eclipsed by the new
GBM standard of care, these results can still inform the development of newer approaches for GBM, either in an earlier, upfront
setting, or by extrapolation of the results and consideration of the use of PEG or IFN in conjunction with other antiglioma strategies.
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Nearly 9000 persons every year are diagnosed with glioblastoma
(GBM) (CBTRUS, 2002) in the United States, and most of them
die within 15 months of diagnosis due to tumour progression.
Deaths occur despite aggressive surgical resection, followed by the
current standard of involved-field radiation plus temozolomide
(TMZ) followed by adjuvant postradiation TMZ chemotherapy
(Stupp et al, 2005). Glioblastomas contain numerous genetic and
epigenetic alterations that allow for their initiation and resistance
to treatment, but a complete understanding of GBM biology is
lacking (Ohgaki and Kleihues, 2007). Due to the incomplete
understanding of GBM biology, difficulties with central nervous
system (CNS) drug delivery, lack of availability of specific and
targeted drugs and other logistic factors, no targeted or cytotoxic
agent has surfaced as a clearly effective treatment for recurrent
GBM patients.
Interferons (IFNs) are naturally occurring glycoproteins with
immunomodulatory, antiproliferative, and antiangiogenic effects
(Kirkwood and Ernstoff, 1984; Blanco et al, 2001; Jonasch and
Haluska, 2001; Maher et al, 2007). The type I IFNs, a and b, are
used in various malignant diseases (Maher et al, 2007). Numerous
studies in glioma patients using both a and b IFNs have demon-
strated possible efficacy. In recurrent GBM patients treated with
intravenous IFNb, combined response rates (objective response
and stable disease) of 51% (Yung et al, 1991) were reported. Other
trials using IFNb have studied both recurrent GBM and post-
radiotherapy GBM patients who were stable (Fine et al, 1997;
Colman et al, 2006) with suggestions of benefit. Varying degrees of
efficacy have been demonstrated using IFNa in recurrent primary
malignant gliomas, either alone or in combination with other
modalities (Boethius et al, 1983; Hirakawa et al, 1983; Nakagawa
et al, 1983; Nagai and Arai, 1984; Mahaley et al, 1985; Obbens et al,
1985; Hamada et al, 1986; Jereb et al, 1989; Yoshida et al, 1994;
Buckner et al, 1995; Dillman et al, 1995; Brandes et al, 1997;
Rajkumar et al, 1998). However, a large phase III trial compared
postradiation BCNU either with or without IFNa, and did not show Received 2 June 2009; revised 18 June 2009; accepted 22 June 2009
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sa benefit with the addition of IFNa (Buckner et al, 2001). A recent
report of a small number of GBM patients suggested a possible
inverse correlation between IFNa gene content and response to
high-dose IFNa (Olson et al, 2004).
IFNa2b is a highly purified human protein produced by
recombinant DNA techniques with indications for several malig-
nant diseases. A formulation of IFNa2b using polyethylene glycol
(PEG-Intron, peg IFNa2b) was developed to allow for longer
patient exposure to drug. Conjugation of IFNa2b with polyethylene
glycol significantly increases its half life (t 1/2) from approximately
4.0 to 40.3 hours, allowing for once a week (QW) dosing.
Temozolomide is a well-tolerated, orally bioavailable alkylating
agent, approved by the Food and Drug Administration (FDA) for
the adjuvant treatment of patients with GBM during and after
radiotherapy. This regimen resulted in a median survival of
14.6 months and a 2-year survival of 26% (Stupp et al, 2005).
Before its approval in the newly diagnosed GBM, TMZ was
commonly used as a cytotoxic agent in combination with a variety
of other antiglioma agents.
Because of the previous data suggesting activity of IFNs in
recurrent GBM, we undertook the studies reported here to
determine whether IFNa2b (standard and pegylated formulation)
along with TMZ at the standard 5-day dosing scheme could
improve 6-month progression-free survival (PFS-6) in patients
with recurrent GBM. As all type I IFNs bind to the same two-
subunit receptor, no significant difference in activity was expected
between IFNa or -b (Maher et al, 2007). Interferon-a2b was chosen
based on its broader history of use in malignant diseases, and on
its ease of acquisition from the pharmaceutical sponsor of the
studies. Results of two studies, TMZ plus IFNa2b (IFN) and TMZ
plus pegylated IFNa2b (PEG) are presented, and both demonstrate
benefit in prolonging PFS-6.
PATIENTS AND METHODS
Inclusion criteria
To be included in these studies, adult patients (X18 years old)
with a Karnofsky performance status (KPS) of X60% must have
had intracranial GBM with evidence of tumour recurrence on CT
or MRI scan of the brain. They must have failed previous radiation
therapy (completed greater than 4 weeks before enrolment), and
be on a stable dose of steroids. Patients may have had up to two
previous chemotherapy regimens for not more than two previous
relapses, and no exposure to either study drug. Patients were
required to sign an institutional review board-approved informed
consent, and to have recovered from effects of previous chemo-
therapy and have adequate organ function.
Study design
Treatment, doses, and evaluations Both studies were single-arm,
open label phase II studies. Both studies used TMZ on a days 1–5
of the 28-day schedule at a starting dose of 200mgm
 2 for patients
not previously treated with any chemotherapy or at 150mgm
 2 for
patients who had received previous chemotherapy. The earlier
study used standard interferon a2b (IFN) and the later study used
PEG. Interferon was dosed at 4 million units (MU)m
 2 per day
subcutaneously (SQ) 3 days per week (Monday, Wednesday,
Friday), days 8 through 28 of each 28-day course. PEG 0.5mgkg
 1
was administered by SQ injection every week. Treatment courses
were repeated every 28 days if all toxicities from the previous
course have resolved to grade 2 or less. For continuation on study
drugs, patients were required to have recovered haematologically
to an absolute neutrophil count of X1500 per ml, platelet count
X100000 per ml, and all drug associated non-haematological
toxicities had to have recovered to either grade 0 or 1. Drugs were
held until recovery from toxicity had occurred. If recovery had not
occurred by day 28, the subsequent course of TMZ was delayed
until the toxicity criteria noted above were met. The dose of TMZ
in subsequent courses was individually titrated and continued
without interruption unless tumour recurrence or progression,
and if toxicity was acceptable. Continuation of therapy after the
first year was decided on an individual basis. For grade 3 or greater
toxicities, treatment was withheld and the patients were monitored
until toxicities resolved to grade 2 or better, then subsequent
courses were started. A minimum of a 2-week rest period was
required for grade 3 or greater toxicity. Dosages for subsequent
courses were one dose level below the dose that produced toxicity
of grade 3 or greater. Dose modifications were allowed based on
patient tolerance. PEG was maintained at the starting dose if well
tolerated, but dose deescalation by 50% (0.25 and then to
0.125mgkg
 1 per week) was allowed. Interferon was started at
4MUm
 2 and could be increased to 5 or 6 MUm
 2, or decreased
to 3 or 2MUm
 2 as needed. Temozolomide could be deescalated
to 175 or 150mgm
 2 (no previous TMZ exposure) or 125 or
100mgm
 2 (previous TMZ exposure) based on drug tolerance.
Only two dose deescalations of IFN, PEG, or TMZ were permitted.
Patients experiencing grade 3 or greater toxicities after two dose
reductions were taken off the study. All patients were maintained
on the lowest steroid dose necessary.
A minimum of 8 weeks of treatment was required for a patient
to be considered as having received an adequate trial to evaluate
efficacy. All patients were evaluable for toxicity and were followed
for at least 30 days after completion of treatment. Any patient
who progressed clinically during the first 8 weeks of therapy was
evaluated by brain MRI scan and considered a protocol failure if
disease progression was documented by neuroimaging. Patients
who, for reasons other than clinical progression, discontinued
treatment before the 8-week time point were not considered
evaluable for efficacy of the treatment and not included in the
PFS-6 determination.
Before enrolment, patients underwent a complete history and
neurological examination, KPS determination, and documentation
of evaluable disease. Pretreatment tests included CBC and standard
blood tests verifying normal organ function, neuropsychological
testing battery and brief fatigue inventory (only some patients),
and contrast enhanced (Gd-DPTA) brain MRI scan. Baseline blood
tests and MRI scans were performed within 14 days of registration.
During participation in the study, patients had routine blood
testing (CBC and organ function tests) on day 22 of every 28-day
course. Every 8 weeks, before odd-numbered courses, patients
underwent contrast-enhanced brain MRI scans, physical and
neurologic examinations with KPS and neuropsychological battery
testing. A subset of patients also completed the brief fatigue
inventory.
Outcome measures The primary endpoint of the study was PFS-6,
but patients were also observed for response to treatment, using
a combination of the neurological examination and MRI brain
scan to define overall response or progression. Bidimensional
measurable lesions were necessary for response evaluation
according to the guidelines promulgated by Macdonald et al
(1990), and were required to be maintained for at least 4 weeks.
Responses were only declared if patients were on no or stable
maintenance doses of corticosteroids, had stable or improved
neurological exams, and were determined, based on MRI changes,
to have a reduction in tumour size. A complete response (CR) was
complete disappearance of all measurable and evaluable disease
and no new lesions, and no evidence of non-evaluable disease.
A partial response (PR) was defined as X50% decrease in the sum
of products of perpendicular diameters of all measurable lesions,
and no new lesions. Stable disease patients were those who did not
qualify for CR, PR, or progression, and required a minimum of
12 weeks duration. Progression was declared when the MRI scan
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lesions over the smallest sum observed (over baseline if no
decrease), or appearance of any new lesion/site, or failure to return
for evaluation due to death or deteriorating condition. Although
the neurological examination was not used for determining
response, it was noted and recorded and used in conjunction with
the imaging data to determine a patient’s overall clinical status.
Patients were described as normal, improved from on-study state,
the same as on-study state, or worse than on-study state (patient
worse). Time to treatment failure was determined from the date of
registration to the date of first observation of progressive disease,
non-reversible neurologic progression, death due to any cause, or
early discontinuation of treatment. Survival was determined from
the date of registration to the date of death (due to any cause).
Steroid dosage was carefully monitored and recorded during each
course of therapy, and steroid dosage changes were considered
before response determinations are made. NCI Clinical Toxicity
Criteria, applicable to the time frame for each study, was used for
toxicity determinations.
Statistical analysis
The primary endpoint for both studies was improvement in PFS-6
(26 weeks). The historical values for comparison were from a
database of 225 recurrent GBM patients enrolled in 8 previous
phase II studies (in which none of the treatments were particularly
effective; Wong et al, 1999). The proportion of patients remaining
alive and free from progression at 6 months was 15% in that
report.
Both studies were single arm by design. For the IFN study,
hypotheses were H0: PpP0 vs H1: PXP1, where P was the
probability of remaining alive and free from progression at
6 months; a (false positive rate) was¼10% and b (false negative
rate)¼5%. P0 was set to 15% (95% CI for the proportion alive
and FFP at 6 months was from 17 to 26%). p1 was set to 35%,
looking for an improvement of 0.2. The plan was to declare success
if 422.5% of patients were alive and free from progression at
6 months, with an a of 7% and a b of 6%. A 35% reponse (PFS-6)
would yield a 95% CI on the true response proportion from 21
to 52%.
For the PEG study, a Simon’s optimal two-stage design was
employed. The hypotheses to be tested were H0: ppp0 vs H1:
pXp1, where p is the probability of remaining alive and free from
progression at 6 months; a was 10%, and b was 5%. p0 was set
to 10% (The 95% confidence interval for our estimate of the
proportion alive and progression free at 6 months was from 10 to
19%.) p1 was set to 30% (looking for an improvement of 0.2).
These parameters led to a trial with a first stage of 20 patients
(stopping if 2 or fewer patients respond) and a total of 40 patients
(declaring success if more than 6 patients respond). As the
outcome was observed over a 6-month period, it was necessary
to suspend enrolment after the first 20 patients were enrolled to
determine if the trial should be stopped or continued.
RESULTS
Patients
For the earlier IFN study, 34 GBM patients were enrolled in 1998 in
less than 5.5 months. For the later PEG study, 29 GBM patients
were enrolled over 39 months from September 2002 through
December 2005. In the PEG study, accrual was halted because of
the establishment of the use of temozolomide as first line
treatment, markedly reducing the number of potentially eligible
patients. Median time from completion of radiation to enrolment
was 24 weeks (range 4–456 weeks) for the IFN study and 22 weeks
(range 4–324 weeks) for the PEG study. In the IFN study, 9 of 34
(26%) patients were enrolled within 3 months of completing
radiation and for the PEG study, this figure was 7 of 29 (24%).
Details of patient demographics are set forth in Table 1. There were
differences between the two groups in the IFN and PEG studies,
but using multivariable logistic regression analysis, no statistically
significant differences were identified between the IFN and PEG
groups with respect to age at diagnosis, KPS at enrolment, gender,
previous extent of resection, or number of previous chemothera-
pies (all results: P40.05).
Response and survival
Eight patients were not evaluable for response and these patients
were not included in the survival analysis. One patient never
received treatment (IFN study), two developed intercurrent
illnesses that caused treatment discontinuance before treatment 1
course was administered (both in the PEG study) and five were
lost to follow-up (four from the IFN study and one from the
PEG study). Six-month progression-free survival was 31% for
29 evaluable patients in the IFN group and 38% for 26 evaluable
patients in the PEG group. Kaplan–Meier survival curves for
PFS-6 are shown in Figure 1. Results for patients enrolled within
the first 3 months after completing radiation (patients with
Table 1 Patient demographics
Parameter TMZ+IFN TMZ+PEG
Number of patients 34 29
Age: median (range) 55 (17–69) 56 (20–67)
Gender: M/F (%) 25:9 (74:26) 16:13 (55:45)
KPS
Median 80 90
100% 3 (9%) 5 (17%)
90% 7 (21%) 16 (55%)
80% 17 (50%) 5 (17%)
70% 7 (21%) 3 (10%)
Maximum prior resection
Biopsy 2 (6%) 5 (17%)
Subtotal resection 20 (59%) 9 (31%)
Gross total resection 12 (35%) 15 (52%)
Number of prior chemotherapies
0 9 (26%) 14 (48%)
1 24 (71%)
a 14 (48%)
b
2 1 (3%) 1 (3%)
aPrior chemotherapies included: topotecan, BCNU, cisplatinum, procarbazine+
CCNU+vincristine (PCV), hydroxyurea, marimastat, 6-thioguanine, 13-cis-retinoic
acid, carboplatin, and etoposide.
bPrior chemotherapies included: celecoxib, gefitinib,
BCNU, CCNU, vincristine, 13-cis-retinoic acid, PCV, tipifarnib, and erlotinib.
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Figure 1 PFS-6 results for TMZþIFN and TMZþPEG.
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spossible pseudoprogression) were a PFS-6 of 12.5% for the IFN
study (n¼9) and 57% for the PEG study (n¼7). Excluding those
patients enrolled within 3 months after completing radiation,
leaves the IFN study with a PFS-6 of 40% and the PEG study with a
PFS-6 of 35%. Additional response and PFS data are presented in
Table 2. Using multivariate Cox proportional hazard regression
analysis, the hazard ratio for progression for the PEG group was
0.63 (95% confidence interval: 0.3, 1.2, P¼0.15). Due to wide a
confidence interval, these results are inconclusive.
Adverse events
All patients except the one from the IFN study who received no
treatment are included in the report of toxicities. In the IFN and
PEG groups, 20 of 33 (60%) and 21 of 29 (72%), respectively, of
patients suffered at least one grade 3 or 4 toxicity event. Details of
the grade 3 and 4 toxicities are presented in Table 3. Of those
patients who had not received previous chemotherapy, 7 of 23
(30%) suffered grade 3 or greater thrombocytopoenia compared to
4 of 40 (10%) of those who had previously received chemotherapy.
Grade 3 or greater leucopoenia occurred in 9 of 23 (39%) and 13 of
40 (33%) of patients who had no previous chemotherapy vs those
who had received previous chemotherapy, respectively. Thus, pre-
vious exposure to chemotherapy did not appear to increase the
risk of grade 3 or greater haematotoxicity in either study. However,
this may have been due to lower TMZ dosing in those patients with
previous chemotherapy exposure.
Neurocognitive testing
Only 11 patients from the PEG study had baseline and at least 2
follow-up neurocognitive assessments. Very little cognitive decline
was seen in these patients, but the quantity of data was felt insuffi-
cient from which to model statistically significant changes or make
conclusions.
DISCUSSION
The current studies were conceived and their enrolment initiated
before FDA approval of TMZ for GBM patients. The 2005 FDA
approval of TMZ for GBM in the upfront setting, and the
subsequent widespread adoption of this regimen (Stupp et al,
2005) resulted in the closure of the PEG study because of low
availability of non-TMZ-treated patients and slow accrual. In the
future, studies using modified dosing schedules of TMZ and/or
combinations of TMZ with newer agents designed to overcome
TMZ resistance might be necessary to ensure adequate accrual.
Additionally, because of the use of TMZ with radiotherapy in the
upfront setting in GBM, these results are somewhat anachronistic.
But this fact does not diminish the study results when compared to
the older data. The new data can serve as building blocks for future
studies of interferons in different settings in glioma.
Despite the incomplete accrual of the second study, we believe
these results provide interesting information, especially when
compared to single-agent TMZ use and to the historical data.
Based on the original statistical designs, the PEG study, but not
the IFN study, met criteria as potentially worthy of further study.
The PFS-6 results of 31 and 38% for IFN and PEG, respectively,
compare favourably to the PFS-6 of 21% reported with standard
(5-day every 28 days) dose TMZ in recurrent GBM (Yung et al,
2000). Even though the demographic differences (higher enrol-
ment KPS, increased percentage of gross total resection, and
lower number of previous chemotherapies) between the patients
in the PEG vs IFN group did not meet statistical significance,
these differences, favouring the PEG group, could have impacted
outcomes.
The reasons for the improved outcomes reported here are not
known, although some hypotheses can be offered. The short arm of
chromosome 9, which contains the IFN gene cluster, is commonly
lost in both primary and secondary GBMs (Maher et al, 2006), as
well as in recurrent high-grade tumours when compared to
low-grade tumours (Kim et al, 1995; Weber et al, 1996). There is
evidence that the short arm of chromosome 9 may contains genes
(IFN or others) with tumour suppressor activity (James et al, 1991,
1993). Malignant glioma specimens are reported to have a 50% rate
of deletion of the IFNa gene cluster (James et al, 1991). Further,
IFNa and -b gene deletions are reported in 26–46% of glioma cell
lines (Miyakoshi et al, 1990; James et al, 1993). These data
notwithstanding, in vitro experiments suggest an antineoplastic
action of IFN treatment, regardless of the IFN gene status of
tumour cells (Miyakoshi et al, 1990). Replacement of IFN protein
may, through a variety of mechanisms, result in an antitumour
effect. Interferon-a results in both direct and indirect immune-
mediated effects (Barth and Morton, 1995), which may be relevant
to the effects seen here. Antiproliferative, antiangiogenic, and
prodifferentiation effects may also be contributing to the
effects seen. Some evidence also suggests IFNs may downregulate
MGMT, increasing tumour cell sensitivity to TMZ (Natsume et al,
2005).
A few features of the adverse event profile of these drug
combinations warrant discussion. First, the risk of grade 3 or 4
anaemia and leucopoenia are almost equivalent to single-agent
TMZ (temozolomide package insert). However, the risk of
lymphopoenia (3%) was remarkably lower than that reported for
single-agent TMZ (55%). Further, no pneumocystis pneumonia
was observed in these patients. Additionally, the risk of thrombotic
events was higher in the PEG-treated patients (17%), as compared
to the IFN-treated ones (0%). The reasons for these observations
Table 2 Response data
Study
6-Month PFS %
(95% CI)
Median PFS months
(95% CI)
Median OS months
(95% CI)
% Responders
(all partial)
% Stable
disease
% Responders+stable
disease
TMZ+IFN; n¼34 31 (16–54)
a 3.6 (3.0–6.3) 7.2 (5.3–10.6) 4/34 (12%) 18/34 (53%) 22/34 (65%)
TMZ+PEG; n¼29 38 (24–64)
a 4.4 (2.4–6.5) 10.0 (7.8–14.3) 1/29 (3%) 17/29 (57%) 18/29 (62%)
aNumbers are n¼29 for TMZ+IFN and n¼26 for TMZ+PEG due to patients being not evaluable for response.
Table 3 Grade 3 and 4 adverse events
Grade 3 or 4 toxicity
IFN study (N¼33):
n (%)
PEG study (N¼29):
n (%)
Leucopoenia 12 (35) 11 (38)
Thrombocytopoenia 6 (18) 6 (21)
Fatigue 6 (18) 6 (18)
Pulmonary embolus/thrombosis 0 (0) 5 (17)
Nausea/vomiting 2 (6) 0 (0)
Headache 0 (0) 2 (7)
Incontinence 0 (0) 2 (7)
Other 2 (3)
a 8 (3)
b
aOne instance each of diarrhoea and elevated transaminases.
bOne instance each of
anaemia, confusion, depression, hypotension, hypoxemia, infection, lymphopoenia,
and pruritis.
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specific patient histories.
Even though the studies reported here appear to show some
benefit over standard dose TMZ in recurrent GBM, several factors
may militate against these results. As both studies are single
institution and non-randomised, their results are less reliable
and may reflect a referral bias. In addition, pseudoprogression
at the time of enrolment in some patients cannot be completely
excluded as a possible contributor to the improved outcomes,
despite its apparent lack of impact when one excludes from
analysis those patients enrolled within 3 months after the
completion of radiotherapy.
CONCLUSIONS
The two phase II studies demonstrated some improvement in
PFS-6 outcomes in recurrent GBM patients as compared with
historical data and with the single-agent TMZ data. The PEG study
met criteria to be deemed worthy of further investigation. The use
of this combination and dosing scheme in the recurrent setting
is probably not feasible at this time, due to the near universal
exposure of GBM patients to TMZ as an up-front treatment.
Possible future avenues of investigation of PEG in malignant
glioma patients could include (1) PEG combined with TMZ and
XRT in the up-front GBM setting (using MGMT methylation status
or IFNa gene content as an enrolment criteria), (2) the addition of
IFN or PEG to an intensified TMZ regimen at recurrence (Wick
et al, 2007), (3) the addition of PEG to alternative cytotoxic
chemotherapies, looking for improvement in outcomes, or (4) the
addition of PEG to other non-cytotoxic therapies, as a potential
synergistic agent.
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